Herrera M, Monge P

Language: Spanish
References: 12
Page: 591-596
PDF size: 203.66 Kb.

ABSTRACT

The Systemic Cutaneous Sclerosis is a disease associated with autoinmune vasculopathy and fibrosis; for a better understanding it’s subdivided into two groups: limited cutaneous and diffuse cutaneous. These groups are classified, depending on the following symptoms: skin patron, affect on internal organs, and the antibody production. The new classification is more suitable to utilize in reality, due to it’s simplicity and preciseness for clinical application; which includes principal signs, symptoms, and specific autoantibodies. The Capillaroscopy is an eminent tool for diagnosis and ongoing, continuing assessments. If the treatment occurs or begins during the window period, complications decrease within internal organs, which alleviate the main causes of mortality, including pulmonary arterial hypertension, intersticial lung disease and renal crisis. For these reasons, the earlier the approach, the extention of survival increases.

REFERENCES

1. Balbir-Guzman A, Braun-Moscovici Y. New aspects in pathogenesis and treatment. Best practice and research clinical rheumatology. 2012; 26: 13- 24.

2. Bustabad S, Rodriguez B, Betherncourt J y Delgado E. Preesclerodermia. Seminarios de la Fundación Española de Reumatología, España. 2011; 12 (4): 123-127.

3. Campos P, et Col. PRESENTACIÓN DE CASO: Esclerosis sistémica y daño renal. Revista Cubana de Medicina. 2013;52(3): 209-213

4. Gabrielli A, Avvedimento E and Krieg T. Mechanisms of disease Sclerodermia. The New England Journal of Medicine. 2009; 360: 1989-2003.

5. García de la Pena Lefebvre P. Aspectos clínicos novedosos en la esclerodermia. Reumatología clínica, España. 2008; 4 supl 1:S45- 9.

6. Hinchclife M and Varga J. Systemic Sclerosis/Scleroderma: a treatable Multisystem Disease. NW University, Chicago, Illinois. American family physician. 2008; 78 (8), 961-969.

7. Harrison. Principios de Medicina Interna. 18ª edición. Editorial Mc GrawHill. Volumen 2. Página.2758.

8. Laborde H, García P, Munoz C. Etiopatogenia de la esclerosis sistémica progresiva. Revista Chilena de Reumatología. 2011; 27 (1): 5-13.

9. Nitsche A. Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatología clínica. 2012; 8 (5): 270-277.

10. Silvarino R, et col. Manifestaciones clínicas en pacientes con esclerosis sistémica. Revista Médica del Uruguay 2009; 25: 84-91

11. Valentini G et al. Early systemic sclerosis: short term disease evolution and factors predicting the development of new manifestations of organ involment. Arthritis research and therapy. 2012; 14: R188

12. Van Der Hoogen F, et al. 2013 Classification criteria for systemic sclerosis. Arthritis and reumatism. 2013; 65: 2737-47